Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Needham & Company LLC from $50.00 to $46.00. They now have a "buy" rating on the stock.
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update [Yahoo! Finance]
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting [Yahoo! Finance]
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting